Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seribantumab - Elevation Oncology

Next Previous
X
Search
Drug Profile

Seribantumab - Elevation Oncology

Alternative Names: MM-121; SAR-256212

Latest Information Update: 12 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merrimack Pharmaceuticals
  • Developer Elevation Oncology; Merrimack Pharmaceuticals; Sanofi
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Suspended Solid tumours
  • Discontinued Gynaecological cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 11 Apr 2024 Interim pharmacodynamics data from a preclinical studies in HER2 expressing cancer released by Elevation Oncology
  • 14 Apr 2023 Safety and efficacy data from a phase II CRESTONE trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 06 Jan 2023 Seribantumab - Elevation Oncology is available for licensing as of 06 Jan 2023. https://elevationoncology.com/our-focus-step-4/# 9378199

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top